跳至主要内容
临床试验/NCT06492746
NCT06492746招募中不适用

Assessing for Personalized Blood Pressure Targets During Cardiopulmonary Bypass With the Proprietary Cerebral Adaptive Index: A Pilot Investigation

Becton, Dickinson and Company2 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2024年6月3日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
120
试验地点
2
主要终点
To determine the magnitude and duration of CAI

研究概览

简要总结

A single-center, prospective, observational pilot of the Cerebral Adaptive Index for assessing personalized blood pressure targets

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
45 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Signed informed consent
  • Age ≥ 45 years
  • Planned cardiac surgery with Cardiopulmonary Bypass (CPB)
  • Planned monitoring with ForeSight sensor and HemoSphere monitor
  • Planned arterial catheterization for blood pressure monitoring
  • High risk for cerebral vascular disease, defined as: a history of hypertension, pulse pressure > 60 mmHg, diabetes, stroke, transient ischemic attack, carotid bruit, tobacco smoking, or peripheral vascular disease

排除标准

  • Non-English speaking
  • Confirmed to be pregnant
  • Surgery for congenital heart defect
  • Non-availability of HemoSphere with laptop CAI interface

研究组 & 干预措施

Cardiopulmonary bypass patients receiving blood pressure and oximetry monitoring

Experimental

干预措施: HemoSphere Advanced Monitoring Platform with Acumen IQ sensor and Tissue Oximetry Monitoring (Device)

结局指标

主要结局

To determine the magnitude and duration of CAI

时间窗: Duration of the procedure through 30 days

To determine the sum of the product of magnitude and duration that CAI during cardiopulmonary bypass (CPB) is at or above the threshold of 45 during current standard of care and assess the incidence of CAI ≥45 in the absence of decreased cerebral StO2 or MAP thresholds.

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验